Chemotherapy in Non-Small Cell Lung Cancer: An Update

A meta-analysis of randomised trials using individual patient data

Protocol B

Comparison 2

Surgery vs neoadjuvant chemotherapy + surgery

Conducted by
the Non-Small Cell Lung Cancer Collaborative Group (NSCLCCG)

April 2004

NSCLC Collaborative Group

Secretariat

Comparisons 1, 2 & 7 please contact

Meta-analysis Group
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
UK
Fax: +44 (0)20 7670 4816

Sarah Burdett
email: sb@ctu.mrc.ac.uk
tel: +44 (0)20 7670 4722

Lesley Stewart
email: ls@ctu.mrc.ac.uk
tel: +44 (0)20 7670 4724

Richard Stephens
email: rs@ctu.mrc.ac.uk
tel: +44 (0)20 7670 4737

Comparisons 3, 4, 5 & 6 please contact

Service de Biostatistique et d'Epidemiologie
Institut Gustave-Roussy
rue Camille Desmoulins
94805 Villejuif cedex
France
Fax: +33 (0)1 42 11 52 58

Anne Auperin
email: auperin@igr.fr
tel: 33 (0) 1 42 11 54 99

Jean-Pierre Pignon
email: jppignon@igr.fr
tel: 33 (0) 1 42 11 45 65

Thierry Le Chevalier
email: tle-che@igr.fr
tel: 33 (0) 1 42 11 43 22

Cecile Le Pechoux
email: lepechoux@igr.fr
tel: 33 (0) 1 42 11 47 57

International Advisory Group

R Arriagada, Instituto de Radiomedicina (IRAM), Santiago 34, Chile
J Higgins, MRC Biostatistics Unit, Cambridge, UK
D Johnson, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
J van Meerbeeck, University Hospital, Ghent, Belgium
M Parmar, MRC Clinical Trials Unit, London, UK
R Souhami, Cancer Research UK, London, UK

Contents

Introduction

More than a million new cases of lung cancer are diagnosed each year[1]. About 80% of these tumours are of non-small cell histological type[2], including adenocarcinomas, squamous cell and large cell carcinomas. Non-small cell lung cancer (NSCLC) is the main cause of deaths from cancer and five-year survival across all stages of disease is about 14%[3].

Surgery is generally regarded as the best treatment option, but only about 30% of tumours are suitable for potentially curative resection[4]. A further 20% of patients, usually those presenting with locally advanced disease, undergo radical thoracic radiotherapy. The remaining 50% of patients, with late stage or metastatic disease, are usually treated palliatively.

In 1991, the British Medical Research Council's Cancer Trials Office (MRC), Cambridge; the Institut Gustave Roussy (IGR), Villejuif, France; and the Istituto Mario Negri (IMN), Milan, Italy initiated an individual patient data (IPD) meta-analysis to assess the role of chemotherapy in the treatment of NSCLC. At that time, despite over thirty years of research involving more than 9000 patients in over 50 randomised clinical trials (RCTs), the efficacy of chemotherapy, when combined with local treatment or supportive care, was unclear. With few exceptions, most trials were too small to reliably detect moderate treatment effects. Consequently, although a few trials reported significant results, both for and against chemotherapy, most trials were inconclusive.

This IPD approach to meta-analysis and systematic review involved the central collection, validation and analysis of the original trial data. It did not rely on data extracted from publications. At the outset, the secretariat contacted the investigators responsible for each trial and established the NSCLC Collaborative Group on whose behalf the meta-analysis was carried out and published in the British Medical Journal in 1995[5]. This has become a 'landmark publication' and was cited nearly 900 times between 1995-2003

The meta-analysis concluded that despite previous scepticism and controversy, modern chemotherapy could have a role in treating NSCLC. In particular, there was strong evidence that for more advanced disease, chemotherapy given in addition to radical radiotherapy and given in addition to best supportive care, prolonged survival. The results for early stage disease, although in favour of chemotherapy, were less clear-cut. A fuller presentation of the results of the meta-analysis published in 1995 is given in Box 1.

The results suggested survival benefits are moderate (~ 5%) but potentially important and that there was no good evidence that any subgroup of patients (age, sex, stage, histology, performance status) benefits more or less than any other group

Since the meta-analysis was published, there has been renewed enthusiasm for investigations of chemotherapy in NSCLC and a considerable number of new RCTs have been completed. The total number of patients randomised has risen from 9387 to around 23000 patients. In particular, there have been many new trials in the surgical setting including trials of neoadjuvant chemotherapy. A number of new agents and timings have been investigated in all settings. As the aim of the NSCLC Collaborative Group is to provide an up to date and reliable review of the role of chemotherapy, both to act as a sound basis for evidence based medicine and to help guide future research, it is now timely to undertake a major update and re-evaluation of the 1995 meta-analysis.

Seven therapeutic comparisons will be explored:

1 surgery vs surgery + adjuvant chemotherapy
2 surgery vs neoadjuvant chemotherapy + surgery
3 surgery + radiotherapy vs surgery + radiotherapy + adjuvant chemotherapy
4 radiotherapy vs radiotherapy + sequential chemotherapy (neoadjuvant – before radiotherapy- and/or adjuvant –after radiotherapy) or alternated radio-chemotherapy
5 radiotherapy vs radiotherapy + concomitant chemotherapy
6 radiotherapy + sequential chemotherapy vs radiotherapy + concomitant chemotherapy
7 supportive care vs supportive care + chemotherapy

Three of these comparisons (2, 5 and 6) are new; this reflects changes in practice and interest since the 1995 Meta-analysis and ensures that this systematic review is as inclusive and comprehensive as possible.

For clarity a separate protocol has been produced for each individual comparison, each of which can be considered as an independent meta-analysis, but when considered together will allow us to evaluate the overall picture of chemotherapy in non-small cell lung cancer.

This protocol relates to **comparison 2** of the meta-analysis, copies of all protocols are available on request or can be downloaded from **http://www.ctu.mrc.ac.uk/download.asp** or **http://www.igr.fr/php/index.php?ids_path=2.51.70.127.567**

The meta-analyses will be jointly run by the Medical Research Council (MRC) and the Institut Gustave-Roussy (IGR). See Appendix D for further meta-analyses completed by these two groups.

Box 1

Summary of Results of 1995 Meta-analysis[1]

The main objective of the meta-analysis was to investigate the effect of chemotherapy on survival when given in addition to appropriate local treatment:

Early disease
surgery versus surgery + chemotherapy
surgery + radiotherapy versus surgery + radiotherapy + sequential chemotherapy
Locally advanced disease
radical radiotherapy versus radical radiotherapy + chemotherapy
Advanced disease
supportive care versus supportive care + chemotherapy

Trials were classified as belonging to one of four pre-specified categories of chemotherapy
-Regimens containing cisplatin
-Regimens using long-term alkylating agents (but not cisplatin)
-Regimens containing etoposide or vinca alkaloids (but not cisplatin)
-Other regimens

Results

Comparison	Hazard Ratio	Confidence Interval	p-value
Surgery vs surgery + chemotherapy			
Long-term alkylating agents	1.15	1.04-1.27	0.005
Other drugs	0.89	0.72-1.11	0.30
Cisplatin based	0.87	0.74-1.02	0.08
Surgery + RT vs surgery + RT + chemotherapy			
Long-term alkylating agents	1.35	0.83-2.20	0.23
Cisplatin based	0.94	0.79-1.11	0.46
Radical RT vs radical RT + chemotherapy			
Long-term alkylating agents	0.98	0.83-1.16	0.81
Vinca-alkaloids	0.87	0.70-1.09	0.23
Other drugs	0.98	0.74-1.29	0.88
Cisplatin based	0.87	0.79-0.96	0.005
Supportive care vs supportive care + chemotherapy			
Long-term alkylating agents	1.26	0.96-1.66	0.095
Vinca-alkaloids / etoposide	0.87	0.64-1.20	0.40
Cisplatin based	0.73	0.63-0.85	<0.0001

A further objective was to assess whether any possible effects were consistent in the subgroups of age, sex, extent of disease, tumour stage, histology and performance status. Subgroup analysis of trials using cisplatin based regimens found no indication that any particular type of patient benefited more or less from chemotherapy.

Conclusions
The results were consistent across primary treatment settings and they tended to show a benefit of modern cisplatin-based chemotherapy regimens although essential drugs were not identified.

[1] Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal 1995;311:899-909.

General Methods

Design

A systematic review and quantitative meta-analysis based on updated individual patient data will be carried out. This approach involves the central collection, validation and analysis of data from all patients from all relevant randomised trials.

Treatment comparisons

Seven meta-analyses will be carried out over three main clinical settings, corresponding to the stage of disease and to the primary treatment

Surgery

1 surgery vs surgery + adjuvant chemotherapy
2 surgery vs neoadjuvant chemotherapy + surgery
3 surgery + radiotherapy vs surgery + radiotherapy + adjuvant chemotherapy

Radiotherapy

4 radiotherapy vs sequential radiotherapy + sequential chemotherapy
5 radiotherapy vs radiotherapy + concomitant chemotherapy
6 radiotherapy + sequential chemotherapy vs radiotherapy + concomitant chemotherapy

Supportive care

7 supportive care vs supportive care + chemotherapy

Identification of trials

There is a great deal of evidence that investigators and journals alike are more likely to publish trials with positive results[6-8]. In order to avoid such publication bias, both published and unpublished trials will be included in the meta-analysis. To identify as many relevant trials as possible, systematic searches of a number of trial sources will be carried out and updated during the course of the project, ensuring a comprehensive and up-to-date database of trials.

Electronic Databases
The optimum search strategy for retrieving randomised controlled trials (RCTs) from Medline, developed by the Cochrane Collaboration[9] will be modified (Appendix B).

- To specifically retrieve RCTs of chemotherapy for NSCLC
- And used to search Medline and Cancerlit

In addition the following electronic bibliographic databases will be searched.

- The Cochrane Central Register of Controlled Trials (CENTRAL)
- Proceedings of the American Society of Clinical Oncology (ASCO) 1995 - 2003

Trial Registers
Trial registers will be used to supplement searches of electronic databases with trials that may not (yet) be published or are still recruiting patients:

- UKCCCR Trials Register
- ClinicalTrials.gov
- Physicians Data Query Protocols (open and closed)
- Current Controlled Trials 'metaRegister' of controlled trials

Hand Searches
The following hand searches will be carried out with the aim of identifying trials that may have only been reported as abstracts or that might have been missed in the searches described above:

- Proceedings of the American Society for Clinical Oncology (ASCO) 1993-1994
- Proceedings of the IASLC World Lung Cancer Conference 1997-2003
- Proceedings of the European Society of Medical Oncology (ESMO) 1996 - 2002
- Proceedings of the European Cancer Conference Organization (ECCO) 1995 - 2003
- Bibliographies of all identified trials and review articles will be searched.

Experts in the field
All participating trialists will be asked to review and supplement a provisional list of trials

Eligibility criteria

2 surgery vs neoadjuvant chemotherapy + surgery

Trials must

- be properly randomised in a way which precludes prior knowledge of treatment assigned
- be unconfounded
- have commenced randomisation on or after January 1st 1965
- have completed accrual (ongoing trials are listed but no data collected) before 2003
- have included patients with non-small cell lung cancer
- have compared first-line chemotherapy

Patients must

- be randomised to receive a) neoadjuvant chemotherapy and surgery or surgery alone or b) neoadjuvant chemotherapy and surgery and postoperative radiotherapy or surgery and postoperative radiotherapy
- not have received prior chemotherapy
- not have had any prior malignancy

Data Collection

Basic survival and baseline characteristics will be sought for **all** patients randomised into each trial. Up to date follow-up will be requested in order to report on both short and longer-term outcomes.

patient identifier (preferably not patient name)
date of birth or age at randomisation
sex
performance status
extent of resection
pre-randomisation tumour stage (cTNM)
pathological tumour stage(pTNM)
histology
date of randomisation
chemotherapy regimen
survival status
date of last follow-up
date of death
cause of death
local recurrence status
date of local recurrence
distant recurrence status
date of distant recurrence
whether excluded from trial analysis
reason for exclusion

Ongoing Trials
It is hoped that as soon as accrual to ongoing trials is completed, the trials have reported and patients have been followed up for a suitable length of time, we can include currently ongoing trials in an update of this meta-analysis.

Suggested coding conventions for these data are provided (Appendix C) and although using them will facilitate data transfer, it is not essential. Data will be accepted in whatever format is most convenient for the individual trial investigator or data centre and can be supplied by email,

computer disk, on data collection forms or as a computer printout. We will also ask for a limited amount of information on trial design as well as the original trial protocol, associated on-study forms and publications

A final copy of the data from each trial will be returned to the trialists for verification. The data collation and checking for **this comparison** will be done by the **MRC**. Copies of the final agreed database of all trials included in all comparisons will be held by the MRC and the IGR. All trial data will be held securely and will not be used, circulated or distributed in any way that allows access to individual trial data, without first seeking permission from trial investigators.

Analysis

The ultimate aim will be to obtain and analyse data from all randomised patients included in all of the relevant randomised trials.

The analysis will be performed on the endpoint of overall survival. Additional analyses will be performed on the endpoints of complete resection rate, local recurrence-free survival, distant recurrence-free survival and overall recurrence-free survival, if sufficient data are available.

All analyses will be of randomised patients and will be carried out by intention to treat, that is, patients will be analysed according to the treatment allocated, irrespective of whether they received that treatment. Survival analyses will be stratified by trial, and the log-rank expected number of deaths and variance will be used to calculate individual and overall pooled hazard ratios by the fixed-effect model[10]. Thus, the times to death for individual patients will be used within trials to calculate the hazard ratio, representing the overall risk of death for patients who were allocated chemotherapy compared to those who were not.

Results will also be presented as absolute differences at relevant time points calculated from the hazard ratio and baseline event rate for patients not allocated chemotherapy;[11] proportional hazards are assumed. Confidence intervals for absolute differences will be similarly calculated from the baseline event rate and the hazard ratio at the 95% CI boundary values. χ^2 heterogeneity tests[5] will be used to test for gross statistical heterogeneity, the I^2 statistic[12] will be used as a measure of consistency. Survival curves will be presented as simple (non-stratified) Kaplan-Meier curves[13]. All p-values will be two-sided.

Analyses by trial level characteristics

The effect of chemotherapy may vary across trials in the meta-analysis because they have each applied treatment in different ways. To explore this further, providing that there are sufficient data available, analyses are planned whereby trials, or arms within trials, will be grouped according to the type of chemotherapy regimen to determine whether there are any differences in treatment effect between these groups.

Trial characteristics will be reported in tabular form, information will include patient numbers, period of recruitment, treatment details, and histological response to chemotherapy.

Type of chemotherapy
It is not practical to look at groups of trials using only exactly the same regimens, nor is it appropriate or sensible to look overall at all trials. We therefore plan to split trials into broad groupings according to the type of chemotherapy used. This will build on the groupings used in the 1995 meta-analysis, which revealed that old trials using long-term oral alkylating agents had a detrimental effect whereas trials using modern regimens showed a beneficial effect

Within each main treatment comparison, trials will be grouped by the type of chemotherapy regimen. If there are insufficient numbers of patients within any categories, categories may be combined.

Platinum based regimens
platinum + vinca alkaloid / etoposide
platinum + anti-metabolic agent (e.g. tegafur, uft)
platinum + taxane
other platinum regimen

Non-platinum based regimens
vinca alkaloid / etoposide only
anti-metabolic agent only
taxane only
other non-platinum regimen

For these analyses a hazard ratio will be calculated for each trial and a pooled hazard ratio calculated for each treatment category. A test for interaction will be used to investigate if there are any substantial differences in the effect of treatment between these treatment categories. If there is no clear evidence of heterogeneity results may also be combined over categories.

Sensitivity Analyses

Hazard ratios for overall survival will also be calculated using a random effects model.

Hazard ratios for overall survival will also be calculated excluding any trials that are clear outliers.

Analyses by patient level characteristics

Providing there are sufficient data available, we will investigate whether any observed treatment effect is consistent across well-defined patient subgroups. These analyses will be carried out on all trials (except trials of long-term alkylating agents) and will be stratified by trial. If there are substantial heterogeneity and differences of effect between treatment categories, then subgroup analyses will be done within treatment categories.

If there are insufficient numbers of patients within any patient categories, categories will be combined. Chi-squared tests for interaction or trend will be used to test whether there is any evidence that particular types of patients benefit more or less from chemotherapy.

The subgroups are as follows:

Age (<60, 60-64, 65-69, 70+)
Sex (Male, Female)
Performance Status *(Good, Poor)
Histology (Adenocarcinoma, Squamous, Large cell, Other)
Stage **See below for calculation

*Performance Status

Meta-analysis Performance Status	WHO / ECOG	Karnofsky
Good	0, 1	100, 90, 80, 70
Poor	2, 3, 4	60 - 10

**Stage

Meta-analysis Stage / ISS 1986	(p)TNM Classification			AJCC Stage	UICC stage 1997
	(p)T	(p)N	(p)M		
I	0,1,2,X,S	0	0	I	IA, IB
II	0,1,2,X,S	1	0	II	IIA, IIB without T3N0
IIIA	a) 3 b) 1-3	a) 0-1 b) 2	0	III non metastatic	IIIA + T3N0
IIIB	4, Any N	3, Any T	0	III non metastatic	IIIB
IV	Any	Any	1	Any metastatic	IV

Alternative exploratory analysis

Given the large number of trial and patient characteristics of interest, there may be interactions between them that could potentially confound these analyses. If we encounter substantial heterogeneity within any of the seven main meta-analyses we will further explore the potential influence of these factors using multi-level modelling techniques.

This modelling aspect of the project will be developed in collaboration with Dr Julian Higgins from the MRC Biostatistics Unit, who is a member of the International Advisory Group.

Publication Policy

The results of the meta-analyses will be published and presented in the name of the NSCLC Collaborative Group comprising trialists contributing data for analysis, the Secretariat and Advisory Group. Following publication in a peer reviewed journal, the meta-analyses will be submitted to the Cochrane Library to appear in the Cochrane Database of Systematic Reviews.

The seven meta-analyses will be analysed separately. We aim to have one collaborators meeting, at which the results will be presented, but the comparisons may be published separately.

The IGR carried out an individual patient data meta-analysis of concomitant chemotherapy (cisplatin or carboplatin) and radiotherapy in locally advanced non-small cell lung cancer. The results were presented at the 2003 World Conference on Lung Cancer in the name of the MAC3-LC (meta-analysis of cisplatin/carboplatin based concomitant chemotherapy in non-small cell lung cancer) Group[14]. This study will be published in the name of this group. The update of this meta-analysis as well as the updating of the comparison on sequential radio-chemotherapy versus radiotherapy alone (comparison 4) and the direct comparison of these two types of radio-chemotherapy (comparison 6) will be published in the name of the current collaborative group.

Project Administration

As for the 1995 Meta-analysis, the MRC and the IGR will share project administration.

Comparisons 1, 2 & 7
The MRC will be responsible for all contact, data collection, verification and analysis for these comparisons.

Comparisons 3, 4, 5 & 6
The IGR will be responsible for all contact, data collection, verification and analysis for these comparisons.

Contacting Trialists

Trialists will be contacted, informed of the project, invited to collaborate and asked to supply data as outlined in the methods section.

Timetable

Spring 2004	Write to Trialists seeking collaboration
Spring 2004-Spring 2005	Collate, check and verify incoming data, analyse individual trials
Summer 2005	Analyses
Autumn 2005	Present results to Trialists

Comparison 2

surgery vs chemotherapy + surgery

Trial	Period of recruitment	Drugs used	Number of patients
Platinum + vinca alkaloid / etoposide			
Roth et al [15]	1987-93	C, Et, Cy	60
JCOG 9209 [16]	1993-97	C, Vd	62
De Boer et al[17]	1995-97	Mi, Vb, C	22
Dautzenberg et al[18]	1985-87	C, Cy, Vd	26
Eberhardt et al [19]	1994-00	C, Et	95
BLT[20]	1995-01	(C, Vd) or (C, Vn) or (C, Mi, If) or (C, Mi, Vn)	13
		Subtotal	*278*
Other platinum regimen			
Rosell et all[21]		C, If, Mi	60
Depierre et al [22]	1991-97	C, If, Mi	373
		Subtotal	*433*
		Total	***711***

Ongoing

Trial	Period of recruitment	Drugs used	Target
Platinum + vinca alkaloid / etoposide			
MRC LU22	Ongoing	(Mi, Vb, C) or (Mi, If, C) or (Vn, C)	450 pts
Platinum + Taxane			
SWOG 9900 (Bunn)	Ongoing	Cy, Px	600 pts
NATCH (Rosell)	Ongoing	C, Dx	600 pts in 3 arms
Other platinum regimen			
Chest (Scagliotti)	Ongoing	C, G	600-700 pts

References

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncology 2001; 2(9):533-43.

2. Rankin EM. Non-small cell lung cancer. In: Slevin ML, Staquet MJ, eds. Randomised clinical trials in cancer: A critical review by site. New York: Raven Press, 1986: 447-92.

3. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer Statistics, 2000. CA: A Cancer Journal for Clinicians 2000; 50(1):7-33.

4. Rudd R. Chemotherapy in the treatment of non-small cell lung cancer. Respiratory Disease in Practice 1991; 7(6):12-4.

5. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal 1995; 311:899-909.

6. Dickersin K. The existence of publication bias and risk factors for its occurrence. Journal of the American Medical Association 1990; 263(10):1385-9.

7. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337(8746):867-72.

8. Dickersin K, Min Y-I, Meinert CL. Factors influencing publication of research results. Journal of the American Medical Association 1992; 267(3):374-8.

9. Lefebvre C, Clarke MJ. Identifying Randomised Trials. In: Egger M, Smith GD, Altman DG, Eds. Systematic Reviews in Healthcare. 2nd edition. London: BMJ Publishing Group, 2002: 69-87.

10. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Progress in Cardiovascular Diseases 1985; 27:335-71.

11. Parmar MKB, Machin D. Survival analysis: a practical approach. John Wiley & Sons Ltd, 1995.

12. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002; 21:1539-58.

13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. Journal of the American Statistical Association 1958; 53:457-81.

14. Auperin A, Le Pechoux C on behalf of the MAC3-LG Group. Meta-analysis of randomized trials evaluating cisplatin or carboplatin-based concomitant chemoradiation versus radiotherapy alone in locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41(Suppl 2):S69.

15. Roth JA, Atkinson EN, Fossella F *et al*. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIa non-small cell lung cancer. Lung Cancer 1998; 21:1-6.

16. Ichinose Y, Tsuchiya R, Kato H. Randomized trial of chemotherapy followed by surgery

versus surgery for stage IIIa non-small cell lung cancer: The Japan clinical oncology group (lung cancer surgery group) 9209. Lung Cancer 2000; 29(Suppl 2):173.

17. de Boer RH, Smith IE, Pastorino U *et al*. Pre-operative chemotherapy in early stage resectable non-small cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial. British Journal of Cancer 1999; 79(9-10):1514-8.

18. Dautzenberg B, Benichou J, Allard P *et al*. Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic non-small cell carcinoma. Cancer 1990; 65:2435-41.

19. Eberhardt W, Korfee S, Wagner H *et al*. "Minimal N2-disease" (operable) stage IIIa non-small cell lung cancer: Prospectively randomized multicenter German phase III trial of surgery (S) followed by adjuvant radiotherapy (RTx) versus "Trimodality treatment" - Early results of feasibility and toxicity in this setting. Lung Cancer 2000; 29(Suppl 1):95.

20. Waller D, Fairlamb DJ, Gower N *et al*. The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting. Proceedings of the American Society of Clinical Oncology 2003; 22:632.

21. Rosell R, Gómez-Codina J, Camps C *et al*. Preresectional chemotherapy in stage IIIa non-small cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 47:7-14.

22. Depierre A, Milleron B, Moro-Sibilot D *et al*. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II and IIIa non-small cell lung cancer. Journal of Clinical Oncology 2002; 20(1):247-53.

Appendix A

Glossary of Drugs

A	Doxorubicin
B	Bleomycin
Bu	Busulphan
C	Cisplatin
Cb	Carboplatin
Cy	Cyclophosphamide
Dx	Docetaxel
E	Epirubicin
Et	Etoposide
G	Gemcitabine
If	Ifosfamide
Lo	Lomustine / CCNU
Me	Mesna
Mi	Mitomycin C
Mx	Methotrexate
Mxa	Mitoxantrone
NM	Nitrogen Mustard
OF	Oral Ftorafur
Pc	Procarbazine
Pe	Pepleomycin
Pm	Porfiromycin
Pr	Prednisolone
Px	Paclitaxel
Tg	Tegafur
Ti	Tirapazamine
Tn	Teniposide
U	UFT (Tegafur + uracil)
Vb	Vinblastine
Vc	Vincristine
Vd	Vindesine
Vn	Vinorelbine

Appendix B

Search Strategy for Medline

1 Randomized Controlled Trial.pt.
2 exp Randomised Controlled Trials/
3 exp Random Allocation/
4 exp Double-Blind Method/
5 exp Single-Blind Method/
6 1 or 2 or 3 or 4 or 5
7 clinical trial.pt.
8 exp Clinical Trials/
9 clin$ with trial.ab,ti.
10 (sing$ or doubl$ or trebl$ or tripl$ with blind$ or mask$).ab, ti.
11 exp Placebos/
12 placebo$.ab.ti.
13 random$.ab,ti.
14 exp Research Design/
15 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16 exp Carcinoma/
17 exp Lung Neoplasms/
18 (lung adj carcinoma$).ab.ti.
19 (lung adj cancer$).ab,ti.
20 (lung adj neoplasm$).ab,ti.
21 cancer with lung.ab,ti.
22 carcinoma with lung.ab,ti.
23 16 or 17
24 18 or 19 or 20 or 21 or 22
25 exp Drug Therapy/
26 drug therapy.ab,ti.
27 chemotherapy.ab,ti.
28 25 or 26 or 27
29 exp radiotherapy/
30 radiotherapy.ab,ti.
31 29 or 30
32 exp surgery/
33 surgery.ab,ti.
34 32 or 33
35 28 or 31 or 34
36 6 or 15
37 36 and 24 and 35

Appendix C

Suggested Coding

Please provide data on all patients randomised. You may complete data forms (provided on request) or supply your data as a computer printout, on floppy disk (formatted for PC) or by email.
Data can be in almost any format (ASCII, Excel, Dbase, FoxPro etc.), but please indicate which format has been used. It would be helpful if you used the coding suggested, however you may code the data in the way that is most convenient for you. Please supply us with full details of the data coding system used if different. If sending data via email, please encrypt the data and let us know how it has been encrypted in a separate email.

Patient Identifier

Preferably not name	
Type	character
Width	15

Date of Birth

Type	date
Width	8 or 6
Code	date in dd/mm/yyyy (recommended) or dd/mm/yy format

Age

Type	numeric
Width	3
Code	age in years unknown=999

Sex

Type	numeric
Width	1
Code	1=male 2=female 9=unknown

Extent of resection

Type	numeric
Width	1
Code	1=complete 2=incomplete 3=no surgery 9=unknown

Tumour stage used before randomisation

Type	numeric
Width	1
Code	1=TNM 2=AJCC 3=1986 ISS 4=1997 UICC

Tumour stage used after surgery

Type	numeric
Width	1
Code	1=pTNM 2=AJCC 3=1986 ISS 4=1997 UICC

If pTNM used

Tumour Stage pTNM

Type	character		
Width	3		
Code	pT Stage	pN Stage	pM stage
	0=pT0	0=pN0	0=pM0
	X=pTX	1=pN1	1=pM1
	S=pTis	2=pN2	9=Unknown
	1=pT1	3=pN3	
	2=pT2	9=Unknown	
	3=pT3		
	4=pT4		
	9=Unknown		

If AJCC used

Tumour Stage AJCC

Type	numeric
Width	1
Code	1=stage 1
	2=stage 2
	3=stage 3
	4=metastatic
	9=unknown

If ISS used

Tumour Stage 1986 ISS

Type	numeric
Width	1
Code	1=stage 1
	2=stage 2
	3=stage 3A
	4=stage 3B
	5=stage 4
	9=unknown

If 1997 staging used

Tumour Stage 1997 UICC

Type	numeric
Width	1
Code	1=stage 1A
	2=stage 1B
	3=stage 2A
	4=stage 2B
	5=stage 3A
	6=stage 3B
	7=stage 4
	9=unknown

Histology

Type	numeric
Width	1
Code	1=small cell
	2=adenocarcinoma
	3=squamous
	4=mixed
	5=large cell undifferentiated
	6=NSC unspecified
	7=other
	9=unknown

*Performance Status (**Karnofsky**)*

Type	numeric
Width	3

	Code	10-100 999=unknown

*Performance Status (**WHO/ECOG**)*

Type	numeric
Width	1
Code	1-4 9=unknown

Treatment Allocated

Type	numeric
Width	1
Code	1=surgery 2=chemotherapy + surgery If more than 1 regimen of chemotherapy used, please specify and use 3,4,5 etc for each different regimen

Date of Randomisation

Type	date
Width	8 or 6
Code	date in dd/mm/yyyy (recommended) or dd/mm/yy format

Survival Status

Type	numeric
Width	1
Code	0=alive 1=dead

Date of Death / Last Follow-up

Type	date
Width	8 or 6
Code	date in dd/mm/yyyy (recommended) or dd/mm/yy format

Cause of Death

Type	numeric
Width	1
Code	1=lung cancer 2=treatment related 3=other 9=unknown

Local Recurrence Status

Type	numeric
Width	1
Code	0=no recurrence 1=recurrence 9=unknown

Date of Local Recurrence

Type	date
Width	8 or 6
Code	date in dd/mm/yyyy (recommended) or dd/mm/yy format

Distant Recurrence Status

Type	numeric
Width	1
Code	0=no recurrence 1=recurrence 9=unknown

Date of Distant Recurrence

Type	date
Width	8 or 6
Code	date in dd/mm/yyyy (recommended) or dd/mm/yy format

Recurrence Status (unspecified local or distant)

Type	numeric
Width	1
Code	0=no recurrence 1=recurrence 9=unknown

Date of Recurrence (unspecified local or distant)

Type	date
Width	8 or 6
Code	date in dd/mm/yyyy (recommended) or dd/mm/yy format

Excluded

Type	numeric
Width	1
Code	0=included in analysis 1=excluded from analysis 9=unknown

Reason for Exclusion

Type	character
Width	25

Appendix D

Completed Individual Patient Data Meta-analyses by MRC and IGR

Meta-analysis Group, MRC Clinical Trials Unit UK

Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. British Medical Journal 1991;303:884-93.

Advanced Bladder Cancer Overview Collaboration. Does neo-adjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomised clinical trials. British Journal of Urology 1995;75:206-13.

Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal 1995;311:899-909.

Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults: meta-analysis of individual patient data. Lancet 1997;350:1647-54.

Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. British Journal of Cancer 1998;78:1479-87.

Arnott SJ, Duncan W, Gignoux M, David GJ, Hansen HS, Launois B, et al. Preoperative radiotherapy in esophagael carcinoma: a meta-analysis using individual patient data (Oesophagael Cancer Collaborative Group). International Journal of Radiation Oncology Biology Physics 1998;41:579-83.

PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. The Lancet 1998;352:257-63.

Glioma Meta-analysis Trialists (GMT) Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.

Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927-34.

Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. European Journal of Cancer 2003;39:2470-86.

Service de Biostatistique et d'Epidemiologie, Institut Gustave-Roussy, France

Pignon J-P, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. New England Journal of Medicine 1992;327:1618-24.

Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal 1995;311:899-909.

Aupérin A, Arriagada R, Pignon J-P, Le Péchoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiaion for patients with small-cell lung cancer in complete remission. The New England Journal of Medicine 1999;341: 476-484.

Pignon JP, Bourhis J, Domenge C, Designé L, on behalf of the MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949-55.

Bourhis J, Syz N, Overgaard J, Ang KK, Dische S, Horiot J, et al. Conventional vs modified fractionated radiotherapy. Meta-analysis of radiotherapy in head & neck carcinoma: a meta-analysis based on individual patient data. International Journal of Radiation Oncology Biology Physics 2002;54(Suppl):71-2.

Piedbois P, Michiels S for the Meta-analysis Group in Cancer. Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: an updated meta-analysis based on 2751 patients. Proceedings of the American Society of Clinical Oncology 2003;22:294.

Auperin A, Le Pechoux C on behalf of the MAC3-LG Group. Meta-analysis of randomized trials evaluating cisplatin or carboplatin-based concomitant chemoradiation versus radiotherapy alone in locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2003;41(Suppl 2):S69.